The ERBB2, TP53, EGFR, NF1, and SETD2 mutations were identified in HER2+ breast cancer as contributing to trastuzumab resistance, whereas in HER2- breast cancer patients with resistance to chemotherapy, genetic variations in the TP53, PIK3CA, and DNA damage repair genes were shown. The gene discussed is PIK3CA; the disease is breast carcinoma.